Background β-thalassemia is one of the most common genetic diseases in the world and requires extensive therapy. Lentiviral-mediated gene therapy has been successfully exploited in the treatment of β-thalassemia and showed promise in clinical application. Using a human β-globin transgenic mouse line in a β-thalassemia diseased model generated with a lentiviral-mediated approach, we investigate the stable therapeutic effect on a common thalassemia syndrome.
Introduction β -thalassemia is one of the most common monogenetic disorders in the world. Globally, there are an estimated 80 million carriers.
1 Severe β-thalassemia is characterized by markedly ineffective erythropoiesis and severe anemia, and patients usually need lifelong blood transfusion. In addition to increased iron absorption, transfusion therapy can lead to progressive iron accumulation and tissue damage in multiple organs. 2 Currently, the most definitive and effective treatment of the disease is believed to be hematopoietic stem cell transplantation. 3, 4 However, allogenic bone marrow transplantation is not an option for the majority of patients without a histocompatible donor. As a result, for the last two decades, treatment of β-thalassemia and hemoglobinopathies (sickle cell anemia) by transplantation of genetically modified autologous hematopoietic stem cells or embryonic stem cells has been considered an important treatment strategy, although the many technical difficulties have made progress slow.
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In 2000, May et al. first reported the alleviation of β-thalassemic symptoms in a mouse model after engraftment of bone marrow cells stably transduced with a lentiviral vector (TNS9) carrying a large fragment of the human β-globin gene. 8 Long-term improvement of clinical symptoms of human β-thalassemia and sickle cell anemia was also reported by other groups using these lentiviral vectors.
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C→T substitution at position IVS-2 nt 654 (β ) in the human β-globin gene is one of the most common β-thalassemia alleles in the Chinese. 12 Patients with β IVS-2-654 mutation lead to abnormally spliced β-globin mRNA with only an approximately 15% normal β-globin gene expression. 13 We report the generation of a human β-globin transgenic mouse in a β IVS-2-654 -thalassemia diseased model mediated by lentiviral vector to investigate the stable therapeutic effect on this common thalassemia syndrome.
Design and Methods

Lentiviral vector construction and production
Human β-globin gene fragment (from -1671 to +1570) was amplified from the human genomic DNA by PCR with specific primers that contained the restriction enzyme Xba I and Kpn I cutting sites (Forward: 5'-TGCTCTAGAGCTCCAGATAGCCATAGAAGAACC-3'-Xba I, Reverse: 5'-GGGGTACCGCGAGCTTAGTGAT-ACTTGT-3'-Kpn I, the cutting sites are underlined). The amplified fragment was digested with Xba I and Kpn I, and then cloned into the corresponding sites of lentiviral vector FUGW.
14 Lentiviral human β-globin gene vector (LBG) is schematically shown in Figure 1A . The most important features of the lentivirus are the CMV enhancer substituted for the U3 region of the 5' LTR (pCL configuration) to maximize expression of viral RNA genomes, the human β-globin promoter from -1671 to +1 to provide erythroid specificity, and a deletion in the U3 region of the 3' LTR to render the 5' LTR of the integrated provirus transcriptionally inactive. The β-globin locus control region (LCR) was omitted because incorporation of hypersensitive (HS) elements was known to render oncoretroviral vectors unstable during passage.
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The vector LBG was co-transfected with ∆R8.9 and VSVG into human embryonic kidney cells 293T. The viral supernatants were collected at 72 hrs after transfection and concentrated by low-speed filtration using 0.2 µm polyethersulfone filter (Hyclone) followed by ultracentrifugation (26,000 rpm, 4ºC for 90 min). The viral was concentrated 1,000-fold from viral supernatants. The crude viral suspension was then quantified by measuring levels of the gag protein, p24 in viral stocks by using the HIV-1 p24 Core Profile ELISA kit from PerkinElmer Life and Analytical Sciences (Boston, MA). A viral aliquot containing 1 pg of p24 gag protein equals 1-10 infectious units (U). Several viral preparations were pooled and the final concentration was approximately 2×10 allele associated with aberrant splicing due to C→T substitution at nt654 of intron 2, characterized by a moder- 
DNA analysis
After the pups weaned (approximately 3 weeks after birth), mouse genomic DNA was isolated from the tail tissue. PCR was then performed to determine lentiviral integration, the allele of human β IVS-2-654 and murine β major with primer pair 1 (5'-GACTTACAAGGCAGCTGTAG-3' and 5'-GTACAGTCCGGATGCAGCTC-3'), primer pair 2 (5'-AGTGATAATTTCTGGGTTAAGGT-3' and 5'-AGGGCCTAGCTTGGACTCAG-3') and primer pair 3 (5'-AGGCAGCTCACAAGAAGAAG-3' and 5'-TGGA-GACTGCTCCCTAGAAT-3') respectively. Reaction was performed in a total volume of 25 µL mixture including 2.5 µL of 10×PCR buffer, 2 µL of MgCl2 (25 mM), 2 µL of dNTP (each 2.5 mM), 0.6 µL of each primer pair (10 pmol/µL each primer), 0.2 µL of Taq enzyme (5 U/µL), adding ddH2O to 25 µL for 30 cycles: denaturing at 94ºC for 45 secs., annealing at 60ºC for 45 secs., and extension at 72ºC for 60 sec.
FISH analysis
The mouse spleen cells were used for FISH analysis according to the methods previously described. 17 To visualize lentiviral vector integration, the corresponding vectors were labeled with the DIG-Nick Translation Kit (Roche, Germany) according to the manufacture's protocol. FISH signals were examined with a Leica DM RXA2 fluorescent microscope.
Human β β-globin mRNA analysis
Total RNA was isolated from the murine fresh peripheral blood using an RNA Extraction Kit (U-gene) according to the manufacturer's instructions. After RT reaction, the correctly spliced human β-globin transcripts were amplified with specific primers (5'-CCTTTGGGGATCT-GTCCACTCCTGA-3' and 5'-CAGCACGTTGC-CCAGGAGCC-3') for 30 cycles in a PCR machine (Eppendorf): denaturating at 94ºC for 45 secs., annealing and extension at 70ºC for 60 secs..
Human β β-globin protein analysis
Fresh peripheral blood from murine tail vein was collected and then lysated. Proteins were separated by 12% SDS-PAGE and then transferred to nylon membrane using the electronic transfer method. Primary human β-globin monoclonal antibody (H00003043-M01, Abnova, 1:1,000 diluted) was used for hybridization at 4ºC for 2 hours. After the primary incubation had been completed, the secondary hybridization was performed using peroxidase conjugated goat anti-mouse IgG (Rockland, 1:1,000 diluted) at 4ºC for another 2 hrs.. Hb bands were visualized by DAB staining. ELISA was also used to quantitatively assess human β-globin contents as previously described.
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Hematologic analysis
Mouse peripheral blood smears were prepared using 1-2 µL of blood samples collected in heparinized microhematocrit tubes, air dried and stained with WrightGiemsa. Whole blood samples from mice starting from 6 weeks of age were collected in 40 µL microhematocrit tubes containing 2 µL of 0.5 M EDTA (pH 8.0). The RBC count, hemoglobin (Hb), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and reticulocyte counts for each sample were determined using the Hematology Analyzer (KX-21, Sysmex) equipped with software to analyze murine cells.
Histopathology
Transgenic mice and age-matched controls (> 1 year old) were used for tissue pathology analysis. Small pieces of livers and spleens were embedded in paraffin wax, cut with a LEICA RM 2135, and then mounted onto glass slides. The tissue sections were stained with hematoxylin-eosin and subsequently examined by light microscopy. Liver tissue sections were also stained with Pearl's Prussian blue to investigate the iron accumulation. Bone marrow smears were stained with Wright-Giemsa staining to calculate the proportion of nucleated cells.
Statistical analysis
The χ 2 test was used to determine difference in Table 1 , and the One Way ANOVA was used to analysis the data in Table 2 . Analytical data were processed using SPSS 11.0 software. 
Results
Efficient generation of transgenic mice using lentiviral vectors by subzonal microinjection
LBG virus particles were microinjected subzonally into 125 single-cell embryos and subsequently implanted into the oviducts of pseudo-pregnant female mice. Twentythree (18.4%) embryos developed to full-term. Eight (34.7%) live-born mice were shown to be positive for LBG integration by PCR analysis.
The birth rate did not differ greatly from those generated by pronuclear injection with similar vectors in our laboratory (18.4% vs. 12.5%). However, the rate of transgene integration seems to be significantly higher in the live-born pups when using the subzonal microinjection method (34.7% vs. 8.0%) (Supplementary Table 1 ).
Germline integration of the lentiviral construct
The live-born mice showed four genotypes according to the PCR results: Hbb /Hbb + mice. Interestingly, a much increased survival rate of 50.0% was observed in F1, and 53.1% in F2 generation of β IVS-2-654 thalassemia mice carrying the human β-globin transgene crossed to wild type mice, suggesting a positive therapeutic effect of the human β-globin transgene (Table 1) .
Stable expression of human β β-globin gene in transgenic mice
RT-PCR was performed to analyze the expression of human β-globin gene in LBG transgenic mice. We found that the correctly spliced transcript (200bp of the amplified fragment) was present in wild type and β IVS-2-654 thalassemia mice that acquired a human β-globin transgene Figure 2D) . Similarly, human β-globin expression was also detected in F1 and F2 generations and sustained a stable level.
Correction of hematologic parameters and improvement of RBC morphology in LBG integrated thalassemia mice
The β hu -Hbb
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/Hbb + mice with stable expression of human β-globin protein also showed marked improve- In addition, a dramatic reduction in reticulocyte numbers from 14.71% to 11.29-11.95% was also found (Table 2) . Furthermore, morphological observation of blood smears revealed a marked decrease in red blood cell anisocytosis, poikilocytosis and target cells from 57.7% to 34.5-36.3% (Table 2, Figure 4A ). /Hbb + mice showed fewer foci of intrasinusoidal EMH ( Figure 4D ) and lower levels of iron accumulation in the livers ( Figure 4E ). The proportion of nucleated cells in bone marrow was also considerably decreased in β 
Pathological changes in spleen
Discussion
Successful treatment of β-thalassemia using lentiviral vectors may lead to a promise of clinical application.
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Previous studies in lentiviral-mediated gene therapy for β-thalassemia were mostly based on the transplantation of genetically modified autologous hematopoietic cells (HSC) in mouse models.
9-11 However, the efficacy of the transgene and the stability of the transgene expression mediated by lentiviral vectors require further investigation. In this study, we generated a human β-globin transgenic mouse line in a β-thalassemia (β ) diseased model with a lentiviralmediated vector, and investigated the effectiveness, inheribility and the positive outcome of this therapeutic approach on a common thalassemia syndrome.
Lentiviral transgenesis by subzonal microinjection was used in the current study. The results indicated that it was more efficient than pronuclear injection. This agrees with the studies by Lois et al. and Hofmann et al. 14, 20 Compared with the pronuclear injection performed in our laboratory, subzonal microinjection can obtain approximately 4 times more transgenic mice. Therefore, subzonal microinjection mediated by lentivirus is a simple and effective method for the generation of transgenic mice.
In this study, a mouse line carrying both normal human β-globin and β IVS-2-654 genes (β /Hbb + mouse) was produced and subsequently observed in detail. Our results showed a stable integration of lentiviral-human β-globin gene vector (LBG) in the genome of the transgenic founders as well as F1 and F2 offspring. Furthermore, a stable level of human β-globin expression was also observed in three generations (Supplementary Figure 7) , indicating germline inheritance of the lentiviral construct and stable expression of the human β-globin transgene. In this study, human β-globin expression was obviously identified in β /Hbb + mice and 0.31g/dL of human β-globin protein was examined in the peripheral blood. Such a stable expression of human β-globin transgene may result in an increase in hemoglobin concentration (Table 2) as well as an improvement in erythropoiesis and thalassemic phenotype in β IVS-2-654 mice. Therapeutic efficacy was also evaluated by investigating the survival rates of β-thalassemia mice in weaned pups. As described in this study, a much higher survival rate (nearly 50%) in β IVS-2-654 pups carrying human β-globin transgene was observed. Obviously, the increased survival rate was due to a positive therapeutic effect and the production of human β-globin partly corrected the defect in thalassemic mice. Nevertheless, cross-breeding will be carried out to expand the numbers of transgenic mice so that we can further analyze the long-term survival of mice which had lentiviral-mediated gene therapy.
Safety issues concerning lentiviral-mediated gene therapy must be considered. 21 One of the concerns about lentiviral vectors is the possibility of insertional activation of cellular oncogenes by random integration of the vector provirus into the host genome. Recently, scientists developed SIN vectors to reduce the risk of insertion mutagenesis which makes lentiviral vector even safer. 22 It is likely that only one or a few copies may integrate the genome of each embryo by subzonal microinjection. Therefore, the risk of insertional mutagenesis for one embryo will be far lower than when transducing lentiviral-mediated transgene to millions of hematopoietic stem cells that will be infused in one mouse. In addition, the mouse model described in this study can be useful to analyze the absence of tissue-dependent toxicity or long-term toxicity of transgenes carried by lentiviral vectors.
In conclusion, we believe that generation of human β-globin transgenic mice using lentiviral vectors could be useful and informative for the pre-clinical assessment of lentiviral-mediated gene therapy in thalassemia and could also be exploited in other diseases.
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